
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences demonstrates a positive financial outlook driven by increased demand and share gains, particularly highlighted by Biktarvy's significant rise to 52% market share in the US, up from 49% in the prior quarter. The company has also provided upward adjustments to its HIV growth guidance, now projecting a year-over-year increase of 5%, despite facing notable Medicare Part D headwinds. Strengthening its diversified portfolio, Gilead's ongoing integration of innovative therapies in oncology and its effective life-cycle management strategy further enhances the potential for sustained revenue growth and market position.
Bears say
Gilead Sciences is experiencing significant challenges across its product portfolio, particularly in the oncology segment, with projected cell therapy sales anticipated to decline by approximately 10% year-over-year in 2025, suggesting ongoing competitive pressures. Additionally, revenue from Veklury has seen a substantial decrease of 60% year-over-year, leading Gilead to lower its FY25 revenue guidance for the drug due to diminishing COVID-19 related hospitalizations and competition. The overall performance in key therapeutic areas, including a 11% year-over-year decline in cell therapy revenues, raises concerns about Gilead's growth prospects and its ability to maintain a robust financial outlook in the near term.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares